The NMIBC market is gaining momentum, with ~13 therapies anticipated to enter key markets by 2034. DelveInsight projects that three critical drugs will secure billion-dollar markets across the 7MM by ...
Professor Peter Nockemann, FRSC, is the Programme Director for the MSc in Pharmaceutical Analysis at QUB. His research focuses on Inorganic and Materials Chemistry, with a keen interest in ...